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The rl-PA Versus Streptoktnase
Controversy-III
T,c preceding letter by Breunwald et al, is designed to neppte the
.c
.urah and vmpottance of the (hones of our cditerel
. The ltiler
was based on the undeserved popalaeiy given to the results of the
II st I /Mt trial . a trial Pawed in several respects and in which the
value of 9p-min potency rates, as determined in that study, was
misirierpretud i
I1
. This fed fu deci eons and a sales of ptbt ieolinns
and prc sr•n
lations that had an enormous influence on the cardiology
community and promoted the use of a very expensive dnnmbolytic
agent those superictils, over other agars in safety . myocardial
salvage, mortality reduction and cost effectiveness has never been
established . The volt has been an unwarranted asperse to the
health care system fur the treatment of acute
my-dial
infarction.
The attiutde of the authors of the letter. who continue to defaml
their position despite the avertshehning information about the lack
of superiority of n-PA over other agents in terms of
a costRreneft!
dik ratio
is
4WRcult to finders trot! oT
m wstifv
. Furthermore their
resistance to appreciating why the results with tt-PA in TIMI Phase
I shmdd not have been interpreted ac representing a remarkable
advance in thrunlbolvtic therapy for acute myocardial tether Lion it
surprising since we have altempled in a series of publications
(2-8)
.
beginning as far back as 1985
. to provide an objective evaluation of
rt-PA and otter thmmholytie agents in the management of acute
myocardial infarction .
In answer to Lenfant's companion letter, it should be noted that
the N HLBI as an authority figure and a public institution needs to be
very cautious in its position relative to a specific agent . The latter
comment refers to the continued use of funds in large amounts to
support trials With rt-PA . a s in the various TIM( studies, in the
absents of any evidence of superiority in safety . myocardial salvage
or mortality reduction (including the lack of any clinical benefit in
the original TIM( Phase I study) over other thmmbolytic agents
.
As for the "valued NHLBI
advisors,"
it should be noted that
this group
. which included some advisors who favored an in-depth
analysis hetore proceeding with TIM[ If or who disagreed with
decisions regarding the organization of future trials . was dropped
under a reorganizaliun plan .
We agree that there is a need now `to focus on future develop-
meals of improved therapies and their expeditious delivery to heart
a:iack victims;' hot this has 'Jean long overdue.
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The rt-PA Versus Streptokinase
Controversy-IV
The probing and provocative editorial of Afonrad (11 will undoubt-
edly he subjected to vigorous rebuttal . However, several of the
issues raised in the editorial bedevil the rlsefu] application of the
results of controlled clinical trials of cardiovascular interventions
other than thrombolysis .
The purpose of such trials is to establish the clinical utility
of
a
particular intervention, medication OF procedure for the prevention
of disease or for the relief of its consequences . The clinical signifi-
cance (nature, magnitude and generalizability of response), logistics
lease of application) and overall cost (cs, no
or alternative lucrapic a)
collectively determine the broad value of medical practice to soci-
ety . Logistic and cost issues me seldom included in the trial design
but must enter into clinical decision-making . In acute myocardial
infarction effective application of thrombolysis must be she respon
.
sibility of emergency room, tamily practice or internal medicine
physicians . A simple, noncomplex procedure will be widely used .
One that is complex in regard to dosing strategy and ancillary
procedures such as heparinization will not be employed, or deferred
to a specialist cardiologist with further undesirable delay .
The conclusions of the TIM] I trial, implying lack of throm-
bolytle efficacy of steeplokinasc and the potential for actual harm
(2), were astonishing to me and my colleagues in 1985 . But one early
data (3,4) ware uncontrolled and observational in nature . In that
year the de facto endorsemenr by the NHLBI of rt-PA as the agent
of choice-without regard to logistics and cost-and the funding of
trials only if ro-PA was the lyric agent strongly discouraged use of
other agents in the Onitod State; . Perhaps a lawyer would argue i hat
selection of streptokinase was below the standard of care! Thus.
Many cardiology trainees in thr second half of the last decade
entered programs ir, which the superiority of ri-PA was established
dogma and the detaled Endings of TIMI and TAMI were required
reading
. These physicians have now entered clinical practice, are
well trained in the application of rt-PA and provide the answer to the
question en preferences by country raised in the accompanying
editorial by Sherry and Murder (5).
It is not my intent to enter into the somewhat irrelevant debate
regarding tae inter to 'prove" superiority of v-PA, clearly an
effective thrembolytic agent . However, to reject the findings of
GISSI and ISIS-studies that reasonably resemble general clinical
practice-undermines the relevancy of all controlled clinical trials .
Indeed, in a program of the American College of Cardiology held at
Lake Louise in March 1992, the respected cardiovascular epidemi-
ologist. Salim Ysuf of the NHLBI poses the interesting tine :
'Impact of Clinical Trials on Thrombolytic Therapy in Clinical
Practice
: Science or marketing?" Controlled clinical trials to refute
prior controlled clinical trials, when funded in large part by com-
.crcial interests, are deserving of critical examination as to actual
purpose. The hope to derive other interesting . perhaps important,
insights is analogous lnPJStifying the space program on the basis of
the biology of weightlessness,
Optimal policy decisions with regard to funding must not be
adversely affected by the singular opinions or powerful persons in
the sceteatihc or regulatory community . Thus research funding on
atherogenesis has been directed at the lipid aspects of the process .
The simplistic, outdated and incomplete hypothesis-chat dietaryfal
intake and its marker, total serum cholesterol, determine adverse
clinical uutcmnes-now
, requires major revision to incorpuralc new
knowledge regarding thrombosis, endolhetiat function, vascular
reactivity and other complex, polygenic multifaclorial mechanisms .
A similar simplistic hypothesis-that an open artery at 91) min would
automatically translate into superior clinical benefit-has now been
shown to be false. Mocrad's commentary, and the accompanying
editorial by Sherry and Marder (5),
are deserving of careful consid-
eration .
Such issues are part of the substrate for the topic of the
President's Page by Robert L . Frye, President of the ACCr'The
Medicare Fee Schedule" (6). If, in the aggregate, expensive inter-
ventions supercede others of wider applicability and substantively
less cost, health care cost containment cannot he achieved .
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Corrections
An error appeared in the article by Hhata et al, in the July 1991
issue of the Journal (Hirata K, Triposkiadis F . Sparks E, Bowen J,
